Market News

Peter Lynch’s GARP strategy reveals PTC Inc (NASDAQ:PTC) as a strong buy. With 25.59% EPS growth, a 0.50 PEG ratio, low debt, and high profitability, ...

Keefe, Bruyette & Woods analyst Ryan Krueger maintains Principal Financial Group (NASDAQ:PFG) with a Market Perform and raises the price target...

Citigroup analyst Jon Tower maintains Yum Brands (NYSE:YUM) with a Neutral and raises the price target from $175 to $178.

The re-intensification of the Middle East war initially roiled the markets, but as the session progressed, oil has pulled back and equities have stabi...

Keefe, Bruyette & Woods analyst Ryan Krueger maintains MetLife (NYSE:MET) with a Outperform and raises the price target from $98 to $105.

The projects are Socrates, Apollo, Aquila, Socrates the Younger, and Neo. The advancement of Williams’ Power Innovation projects demonstrates the uniq...

Investing.com -- Global chip stocks fell sharply Monday, led by a record one-day plunge in SK Hynix shares, as investors weighed a fresh escalation in...

Investing.com -- Global chip stocks fell sharply Monday, led by a record one-day plunge in SK Hynix shares, as investors weighed a fresh escalation in...

Keefe, Bruyette & Woods analyst Ryan Krueger maintains Lincoln National (NYSE:LNC) with a Outperform and raises the price target from $44 to $4...

Citigroup analyst John Godyn maintains Delta Air Lines (NYSE:DAL) with a Buy and raises the price target from $106 to $110.

Keefe, Bruyette & Woods analyst Ryan Krueger maintains Jackson Financial (NYSE:JXN) with a Market Perform and raises the price target from $125...

Keefe, Bruyette & Woods analyst Ryan Krueger maintains Genworth Financial (NYSE:GNW) with a Outperform and raises the price target from $11 to ...

Keefe, Bruyette & Woods analyst Ryan Krueger maintains Globe Life (NYSE:GL) with a Outperform and raises the price target from $180 to $192.

Wedbush analyst David Nierengarten reiterates Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and maintains $55 price target.

Exited ClearPoint Neuro (CLPT): revenue growth can’t offset -60%+ margins, negative cash flow and dilution risk.

Keefe, Bruyette & Woods analyst Ryan Krueger maintains Equitable Holdings (NYSE:EQH) with a Outperform and raises the price target from $60 to ...

Keefe, Bruyette & Woods analyst Ryan Krueger maintains Corebridge Financial (NYSE:CRBG) with a Outperform and raises the price target from $38 ...

AeroVironment, Inc. ("AV") (NASDAQ:AVAV), a global defense technology leader, today announced that it has received an MQ-31A military designat...

Keefe, Bruyette & Woods analyst Ryan Krueger maintains CNO Finl Group (NYSE:CNO) with a Market Perform and raises the price target from $50 to ...

Micron Technology (MU) passes the Decent Value screen, combining a strong 9/10 valuation score with top-tier profitability, accelerating growth, and a...